Home > Result Summaries: Compounds > GSK202405 Result Summaries: GSK202405 GSKStudy ID Phase Title Summary (Download) 101824 Phase 1 A single-centre, randomized, double blind, placebo-controlled, double-dummy, dose escalating cross-over study to examine the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single inhaled doses of a new chemical entity and salmeterol (50 µg via DPI) in COPD patients. (0 citation(s))
